Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes.

Structure-activity relationship studies directed toward the optimization of (2S)-2-(3-chlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[4-(substituted)piperidin-1-yl]butanes as CCR5 antagonists resulted in the synthesis of the spiro-indanone derivative 8c (IC50=5 nM). These and previous results are summarized in a proposed pharmacophore model for this class of CCR5 antagonist.

[1]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[2]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[3]  T. Halgren.  MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries , 1999, Journal of computational chemistry.

[4]  B. D. Harris,et al.  Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1). , 1996, The Journal of organic chemistry.

[5]  M. Maccoss,et al.  A facile synthesis of the novel neurokinin A antagonist SR 48968 , 1993 .

[6]  Anthony S. Fauci,et al.  Host factors and the pathogenesis of HIV-induced disease , 1996, Nature.

[7]  O. Nishimura,et al.  Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. , 2000, Journal of medicinal chemistry.

[8]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[9]  R. C. Elderfield,et al.  Action of Metal Hydrides on β-(3-Indolyl)ethyl-1-pyridinium Salts*1,2 , 1957 .

[10]  Blair,et al.  HIV-1 entry - an expanding portal for drug discovery. , 2000, Drug discovery today.

[11]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[12]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[13]  J. Mascola,et al.  The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression , 1997, Nature Medicine.

[14]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.